XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Retained Earnings
Accumulated Other Comprehensive Income (Lossses)
Treasury Stock
Balance at beginning of period (in shares) at Dec. 31, 2020   52,536,482        
Balance at beginning of period at Dec. 31, 2020 $ 404,879 $ 755 $ 644,695 $ 107,233 $ 7,633 $ (355,437)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 3,217     3,217    
Foreign currency translation (303)       (303)  
Stock-based compensation (in shares)   101,083        
Stock-based compensation 2,032 $ 1 2,031      
Stock repurchase (in shares)   (1,038,674)        
Stock repurchase (19,321)         (19,321)
Common stock dividends (3,967)     (3,967)    
Unrealized (loss) gain on derivative instruments 14,530       14,530  
Stock option exercises (in shares)   112,400        
Stock option exercises 1,235 $ 1 1,234      
Balance at end of period (in shares) at Mar. 31, 2021   51,711,291        
Balance at end of period at Mar. 31, 2021 402,302 $ 757 647,960 106,483 21,860 (374,758)
Balance at beginning of period (in shares) at Dec. 31, 2020   52,536,482        
Balance at beginning of period at Dec. 31, 2020 404,879 $ 755 644,695 107,233 7,633 (355,437)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 26,477          
Foreign currency translation 259          
Unrealized (loss) gain on derivative instruments 13,974          
Balance at end of period (in shares) at Sep. 30, 2021   49,574,651        
Balance at end of period at Sep. 30, 2021 386,194 $ 759 652,530 121,495 21,866 (410,456)
Balance at beginning of period (in shares) at Mar. 31, 2021   51,711,291        
Balance at beginning of period at Mar. 31, 2021 402,302 $ 757 647,960 106,483 21,860 (374,758)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 12,252     12,252    
Foreign currency translation 667       667  
Stock-based compensation (in shares)   37,147        
Stock-based compensation 2,184 $ 1 2,183      
Stock repurchase (in shares)   (1,304,214)        
Stock repurchase (21,981)         (21,981)
Common stock dividends (4,290)     (4,290)    
Unrealized (loss) gain on derivative instruments 8,631       8,631  
Stock option exercises (in shares)   19,810        
Stock option exercises 215   215      
Balance at end of period (in shares) at Jun. 30, 2021   50,464,034        
Balance at end of period at Jun. 30, 2021 399,980 $ 758 650,358 114,445 31,158 (396,739)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 11,008     11,008    
Foreign currency translation (105)       (105)  
Stock-based compensation (in shares)   1,799        
Stock-based compensation 1,673   1,673    
Stock repurchase (in shares)   (935,382)        
Stock repurchase (13,717)         (13,717)
Common stock dividends (3,958)     (3,958)    
Unrealized (loss) gain on derivative instruments (9,187)       (9,187)  
Stock option exercises (in shares)   44,200        
Stock option exercises 500 $ 1 499      
Balance at end of period (in shares) at Sep. 30, 2021   49,574,651        
Balance at end of period at Sep. 30, 2021 386,194 $ 759 652,530 121,495 21,866 (410,456)
Balance at beginning of period (in shares) at Dec. 31, 2021   48,954,482        
Balance at beginning of period at Dec. 31, 2021 325,539 $ 759 653,978 92,111 859 (422,168)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 12,074     12,074    
Foreign currency translation 243       243  
Stock-based compensation (in shares)   277,124        
Stock-based compensation 2,277 $ 5 2,272      
Stock repurchase (in shares)   (247,174)        
Stock repurchase (8,013)         (8,013)
Common stock dividends (4,065)     (4,065)    
Unrealized (loss) gain on derivative instruments 13,585       13,585  
Stock option exercises (in shares)   48,208        
Stock option exercises 613   613      
Balance at end of period (in shares) at Mar. 31, 2022   49,032,640        
Balance at end of period at Mar. 31, 2022 342,253 $ 764 656,863 100,120 14,687 (430,181)
Balance at beginning of period (in shares) at Dec. 31, 2021   48,954,482        
Balance at beginning of period at Dec. 31, 2021 325,539 $ 759 653,978 92,111 859 (422,168)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 70,796          
Foreign currency translation (140)          
Unrealized (loss) gain on derivative instruments (8,193)          
Balance at end of period (in shares) at Sep. 30, 2022   48,065,277        
Balance at end of period at Sep. 30, 2022 360,102 $ 765 662,581 150,943 (7,474) (446,713)
Balance at beginning of period (in shares) at Mar. 31, 2022   49,032,640        
Balance at beginning of period at Mar. 31, 2022 342,253 $ 764 656,863 100,120 14,687 (430,181)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 22,552     22,552    
Foreign currency translation (303)       (303)  
Stock-based compensation (in shares)   16,416        
Stock-based compensation 2,370 2,370      
Stock repurchase (in shares)   (360,659)        
Stock repurchase (5,312)         (5,312)
Common stock dividends (3,901)     (3,901)    
Unrealized (loss) gain on derivative instruments (19,610)       (19,610)  
Stock option exercises (in shares)   12,690        
Stock option exercises 122   122      
Balance at end of period (in shares) at Jun. 30, 2022   48,701,087        
Balance at end of period at Jun. 30, 2022 338,171 $ 764 659,355 118,771 (5,226) (435,493)
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income 36,170     36,170    
Foreign currency translation (80)       (80)  
Stock-based compensation (in shares)   3,344        
Stock-based compensation 2,720   2,720    
Stock repurchase (in shares)   (691,844)        
Stock repurchase (11,220)         (11,220)
Common stock dividends (3,998)     (3,998)    
Unrealized (loss) gain on derivative instruments (2,168)       (2,168)  
Stock option exercises (in shares)   52,690        
Stock option exercises 507 $ 1 506      
Balance at end of period (in shares) at Sep. 30, 2022   48,065,277        
Balance at end of period at Sep. 30, 2022 $ 360,102 $ 765 $ 662,581 $ 150,943 $ (7,474) $ (446,713)